Send me real-time posts from this site at my email
Zacks

Rite Aid (RAD) to Report Q2 Earnings: What Should You Know?

Rite Aid Corporation RAD is scheduled to report second-quarter fiscal 2022 results on Sep 23, before the opening bell. The Zacks Consensus Estimate for its fiscal second-quarter revenues is pegged at $6.25 billion, suggesting a 4.4% increase from the prior-year quarter’s reported figure of $5.98 billion. The Zacks Consensus Estimate for fiscal second-quarter earnings is pegged at a loss of 42 cents, whereas it reported earnings of 25 cents in the year-ago quarter. The consensus mark has been unchanged in the past 30 days.

In the last reported quarter, the drugstore retailer’s earnings beat estimates by 72.7%. The company has an earnings surprise of 1,075.3%, on average, for the trailing four quarters.

Key Factors to Note

Rite Aid has been gaining from the expansion of delivery services to customers. Some notable efforts include free-of-charge home delivery service with an eligible prescription, pick-up services, drive-through for prescriptions and over-the-counter products, Buy Online Pickup In Store initiative, and curbside pickup options.

Rite Aid also expanded the Instacart delivery service and made partnerships with Amazon, Postmates and Instacart for home delivery, which have been contributing to digital sales growth. The company partnered with DoorDash and Shipt to offer same-day delivery of non-prescription health, convenience and wellness essentials. Rite Aid made collaboration with ScriptDrop to expedite the prescription delivery process. Such endeavors should have aided fiscal second-quarter results.

The company is progressing well with its efforts to strengthen the foothold in mid-market PBM by innovation across its retail and mail-order pharmacy channels, enhanced in-store experience, curated digital offerings, improved merchandise, and rebranded image with a new logo. Rite Aid’s newly launched Stores of the Future and the acquisition of Bartell are likely to have helped expand the customer base. Alongside these, its RxEvolution strategy is expected to have aided it.

However, the company has continued to witness elevated expenses due to a rise in wages and increased investments to drive revenues. This is likely to have persisted in the quarter under review. Sluggishness in front-end same-store sales, owing to lower demand for general cleaning products, sanitizers, wipes, paper products, liquor, and over-the-counter products, is expected to have acted as a deterrent. With the pandemic slowly fading away, lesser cases of cough, cold, and flu are expected to have been limited in the fiscal second quarter.

Rite Aid Corporation Price and EPS Surprise

 

Rite Aid Corporation price-eps-surprise | Rite Aid Corporation Quote

What the Zacks Model Unveils

Our proven model does not conclusively predict an earnings beat for Rite Aid this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Rite Aid has a Zacks Rank #3 and an Earnings ESP of 0.00%.

Stocks Poised to Beat Earnings Estimates

Here are some companies you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat:

Costco Wholesale Corporation COST currently has an Earnings ESP of +0.11% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Darden Restaurants DRI has an Earnings ESP of +1.69%. It presently carries a Zacks Rank #3.

Walgreens Boots Alliance WBA currently has an Earnings ESP of +2.15% and a Zacks Rank #3.


Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Rite Aid Corporation (RAD): Free Stock Analysis Report
 
Darden Restaurants, Inc. (DRI): Free Stock Analysis Report
 
Costco Wholesale Corporation (COST): Free Stock Analysis Report
 
Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue